Jump To Jump To Watch View Summit Archive Immuno-Oncology and Personalized Medicine April 8, 2022 Shelby Moneer, Vice President, Patient Programs & Education, ZERO - The End of Prostate Cancer is talking about immuno-oncology and personalized medicine with Dr. Michael Groaning, Prostate Cancer Global Medical Affairs Lead, Amgen. Their specific focus is on advancing prostate cancer treatment with T-cell engagers and emerging therapeutic targets.This session was part of our VIRTUAL ZERO Prostate Cancer Summit, which took place from March 4 to 8, 2022.Watch Summit Session Archives At each ZERO Summit, you'll experience the Bold for Blue Awards, educational sessions, advocacy training, and more. See the video archives to find more of what you can expect to see when you join us at this year’s Summit! View Summit Archive Living with Prostate Cancer Testing & Diagnosis Treatment Options Videos & Webinars ZERO Prostate Cancer Summit Contributors Michael Groaning, PhD, Prostate Cancer Global Medical Affairs Lead Dr. Groaning attended Colorado State University until 2000 when he moved to Zurich, Switzerland for his post-doctoral studies at the Swiss Federal Institute of Technology (ETH). Dr. Groaning started his career in the pharmaceutical industry at F. Hoffmann – La Roche in Basel, Switzerland in their Discovery Chemistry group before transferring to Boulder, Colorado as a process research chemist where he optimized the production of a key intermediate for Tamiflu. Shelby Moneer, Vice President, Patient Programs & Education Missouri native dreaming of the beaches in basically any location that isn't land-locked. Lover of exercise, sports, candy, sushi, and coffee. Fiercly loyal to my family and friends. Learn more about Shelby Jamie Bearse, Past President Past President of ZERO Cancer between 2002-2023, Jamie was instrumental as a leader, mentor, advocate, and champion for the families we serve. Want to connect with ZERO? We look forward to hearing from you at info@zerocancer.org! More for you
Shelby Moneer, Vice President, Patient Programs & Education, ZERO - The End of Prostate Cancer is talking about immuno-oncology and personalized medicine with Dr. Michael Groaning, Prostate Cancer Global Medical Affairs Lead, Amgen. Their specific focus is on advancing prostate cancer treatment with T-cell engagers and emerging therapeutic targets.This session was part of our VIRTUAL ZERO Prostate Cancer Summit, which took place from March 4 to 8, 2022.Watch
Summit Session Archives At each ZERO Summit, you'll experience the Bold for Blue Awards, educational sessions, advocacy training, and more. See the video archives to find more of what you can expect to see when you join us at this year’s Summit! View Summit Archive
Living with Prostate Cancer Testing & Diagnosis Treatment Options Videos & Webinars ZERO Prostate Cancer Summit
